Syndax Patent-Cliff Exposure & CMS Drug Spending Portfolio

Syndax (US): 1 reconciled FDA prescription therapies, $1.1M 2024 CMS Part D & Medicaid spend, and $19,750 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$1.1M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($19,750 intro WAC)